{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:20:47Z","timestamp":1792484447301,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82572274"],"award-info":[{"award-number":["82572274"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82372005"],"award-info":[{"award-number":["82372005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82171986"],"award-info":[{"award-number":["82171986"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81871391"],"award-info":[{"award-number":["81871391"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00259-026-07813-6","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:54:39Z","timestamp":1772240079000},"page":"4572-4586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["[68Ga]Ga-Pentixafor PET\/CT for Durie-Salmon PLUS staging and risk stratification in newly diagnosed multiple myeloma"],"prefix":"10.1007","volume":"53","author":[{"given":"Jie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaihu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueli","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diankui","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongjiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9846-7578","authenticated-orcid":false,"given":"Yong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"7813_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10:45. https:\/\/doi.org\/10.1038\/s41572-024-00529-7.","journal-title":"Nat Rev Dis Primers"},{"key":"7813_CR2","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324. https:\/\/doi.org\/10.1002\/ajh.27422.","journal-title":"Am J Hematol"},{"key":"7813_CR3","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, et al. EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025;22:680\u2013700. https:\/\/doi.org\/10.1038\/s41571-025-01041-x.","journal-title":"Nat Rev Clin Oncol"},{"key":"7813_CR4","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF, et al. International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. J Clin Oncol. 2025;43:2739\u201351. https:\/\/doi.org\/10.1200\/JCO-24-01893.","journal-title":"J Clin Oncol"},{"key":"7813_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf299","volume":"30","author":"M Baysal","year":"2025","unstructured":"Baysal M, Julian K, Sborov D, Godara A, McClune B, Lohr JG, et al. The past, present and future of myeloma staging and risk prognostication. Oncologist. 2025;30:oyaf299. https:\/\/doi.org\/10.1093\/oncolo\/oyaf299.","journal-title":"Oncologist"},{"key":"7813_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01268-y","volume":"15","author":"C Brieghel","year":"2025","unstructured":"Brieghel C, Slordahl TS, Andersen MN, Szabo AG, Niemann CU, Thorsteinsdottir S. A real-world International staging system (RW-ISS) for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2025;15:59. https:\/\/doi.org\/10.1038\/s41408-025-01268-y.","journal-title":"Blood Cancer J"},{"key":"7813_CR7","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D'Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40:3406\u201318. https:\/\/doi.org\/10.1200\/JCO.21.02614.","journal-title":"J Clin Oncol"},{"key":"7813_CR8","unstructured":"Mayo Clinic Treatment Guidelines: Multiple Myeloma-mSMART Risk Stratification of Newly Diagnosed Myeloma. https:\/\/www.msmart.org\/mm-treatment-guidelines. Accessed 2 June 2025."},{"key":"7813_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1148\/radiol.10091809","volume":"257","author":"K Fechtner","year":"2010","unstructured":"Fechtner K, Hillengass J, Delorme S, Heiss C, Neben K, Goldschmidt H, et al. Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems. Radiology. 2010;257:195\u2013204. https:\/\/doi.org\/10.1148\/radiol.10091809.","journal-title":"Radiology"},{"key":"7813_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06621-0","author":"Z Chen","year":"2024","unstructured":"Chen Z, Yang A, Chen A, Dong J, Lin J, Huang C, et al. [68Ga]Pentixafor PET\/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2024;51:1926\u201336. https:\/\/doi.org\/10.1007\/s00259-024-06621-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7813_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00259-019-04312-9","volume":"46","author":"Y Abe","year":"2019","unstructured":"Abe Y, Ikeda S, Kitadate A, Narita K, Kobayashi H, Miura D, et al. Low hexokinase-2 expression-associated false-negative 18F-FDG PET\/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging. 2019;46:1345\u201350. https:\/\/doi.org\/10.1007\/s00259-019-04312-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7813_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-014-0308-3","volume":"15","author":"F Dammacco","year":"2015","unstructured":"Dammacco F, Rubini G, Ferrari C, Vacca A, Racanelli V. 18F-FDG PET\/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. Clin Exp Med. 2015;15:1\u201318. https:\/\/doi.org\/10.1007\/s10238-014-0308-3.","journal-title":"Clin Exp Med"},{"key":"7813_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.15252\/emmm.201404698","volume":"7","author":"K Philipp-Abbrederis","year":"2015","unstructured":"Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Luckerath K, et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015;7:477\u201387. https:\/\/doi.org\/10.15252\/emmm.201404698.","journal-title":"EMBO Mol Med"},{"key":"7813_CR14","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2967\/jnumed.121.263693","volume":"63","author":"AK Buck","year":"2022","unstructured":"Buck AK, Haug A, Dreher N, Lambertini A, Higuchi T, Lapa C, et al. Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using 68Ga-Pentixafor PET. J Nucl Med. 2022;63:1687\u201392. https:\/\/doi.org\/10.2967\/jnumed.121.263693.","journal-title":"J Nucl Med"},{"issue":"1","key":"7813_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7150\/thno.16576","volume":"68","author":"C Lapa","year":"2017","unstructured":"Lapa C, Schreder M, Schirbel A, Samnick S, Kortum KM, Herrmann K, et al. [68Ga]pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [18F]FDG and laboratory values. Theranostics. 2017;68(1):205\u201312. https:\/\/doi.org\/10.7150\/thno.16576.","journal-title":"Theranostics"},{"key":"7813_CR16","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1097\/RLU.0000000000005426","volume":"50","author":"M Chavoshi","year":"2025","unstructured":"Chavoshi M, Mirshahvalad SA, Kohan A, Ortega C, Metser U, Farag A, et al. CXCR4-targeted PET imaging in hematologic malignancies: a systematic review and meta-analysis. Clin Nucl Med. 2025;50:e7\u201316. https:\/\/doi.org\/10.1097\/RLU.0000000000005426.","journal-title":"Clin Nucl Med"},{"key":"7813_CR17","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20211272","volume":"95","author":"AS Shekhawat","year":"2022","unstructured":"Shekhawat AS, Singh B, Malhotra P, Watts A, Basher R, Kaur H, et al. Imaging CXCR4 receptors expression for staging multiple myeloma by using 68Ga-Pentixafor PET\/CT: comparison with 18F-FDG PET\/CT. Br J Radiol. 2022;95:20211272. https:\/\/doi.org\/10.1259\/bjr.20211272.","journal-title":"Br J Radiol"},{"key":"7813_CR18","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s12149-021-01652-1","volume":"35","author":"S Kuyumcu","year":"2021","unstructured":"Kuyumcu S, Isik EG, Tiryaki TO, Has-Simsek D, Sanli Y, Buyukkaya F, et al. Prognostic significance of 68Ga-Pentixafor PET\/CT in multiple myeloma recurrence: a comparison to 18F-FDG PET\/CT and laboratory results. Ann Nucl Med. 2021;35:1147\u201356. https:\/\/doi.org\/10.1007\/s12149-021-01652-1.","journal-title":"Ann Nucl Med"},{"key":"7813_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2025.109156","volume":"181","author":"N Lu","year":"2025","unstructured":"Lu N, Chen L, Yu F, Xiao Z, Xing D, Zhong J, et al. Evaluating the value of chemokine receptor type 4-targeted PET imaging in diagnosing primary aldosteronism lateralization: a comparison with adrenal venous sampling. Surgery. 2025;181:109156. https:\/\/doi.org\/10.1016\/j.surg.2025.109156.","journal-title":"Surgery"},{"key":"7813_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","volume":"47","author":"Q Pan","year":"2020","unstructured":"Pan Q, Cao X, Luo Y, Li J, Feng J, Li F. Chemokine receptor-4 targeted PET\/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2020;47:537\u201346. https:\/\/doi.org\/10.1007\/s00259-019-04605-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7813_CR21","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche C, Orlhac F, Boughdad S, Reuze S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78:4786\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0125.","journal-title":"Cancer Res"},{"key":"7813_CR22","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.230667","volume":"308","author":"DK Kim","year":"2023","unstructured":"Kim DK, Jung JY, Kim H, Lee S, Lee SY, Lee S, et al. Development of a semiquantitative whole-body MRI scoring system for multiple myeloma. Radiology. 2023;308:e230667. https:\/\/doi.org\/10.1148\/radiol.230667.","journal-title":"Radiology"},{"key":"7813_CR23","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.7150\/ijbs.82317","volume":"19","author":"Y Yang","year":"2023","unstructured":"Yang Y, Li J, Lei W, Wang H, Ni Y, Liu Y, et al. CXCL12-CXCR4\/CXCR7 axis in cancer: from mechanisms to clinical applications. Int J Biol Sci. 2023;19:3341\u201359. https:\/\/doi.org\/10.7150\/ijbs.82317.","journal-title":"Int J Biol Sci"},{"key":"7813_CR24","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.25.32708","volume":"225","author":"W Wang","year":"2025","unstructured":"Wang W, Huang M, Tian R, Shen G. Head-to-head comparison of 68Ga-PentixaFor PET\/CT and FDG PET\/CT for detecting hematologic and solid cancers: a systematic review and meta-analysis. AJR Am J Roentgenol. 2025;225:e2532708. https:\/\/doi.org\/10.2214\/AJR.25.32708.","journal-title":"AJR Am J Roentgenol"},{"key":"7813_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01190-9","volume":"14","author":"R Nakamoto-Matsubara","year":"2024","unstructured":"Nakamoto-Matsubara R, Nardi V, Horick N, Fukushima T, Han RS, Shome R, et al. Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma. Blood Cancer J. 2024;14:224. https:\/\/doi.org\/10.1038\/s41408-024-01190-9.","journal-title":"Blood Cancer J"},{"key":"7813_CR26","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.1158\/1078-0432.CCR-16-0866","volume":"22","author":"O Landgren","year":"2016","unstructured":"Landgren O, Rajkumar SV. New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. Clin Cancer Res. 2016;22:5428\u201333. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0866.","journal-title":"Clin Cancer Res"},{"key":"7813_CR27","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1007\/s11307-024-01953-7","volume":"26","author":"Q Yang","year":"2024","unstructured":"Yang Q, Zhang F, Hao Z, Zhuang J, Huo L. Chemokine receptor 4-targeted PET\/CT with [68Ga]pentixather in newly diagnosed multiple myeloma: a comparative study with [68Ga]pentixafor PET\/CT. Mol Imaging Biol. 2024;26:986\u201394. https:\/\/doi.org\/10.1007\/s11307-024-01953-7.","journal-title":"Mol Imaging Biol"},{"key":"7813_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/leu.2008.299","volume":"23","author":"JA Burger","year":"2009","unstructured":"Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009;23:43\u201352. https:\/\/doi.org\/10.1038\/leu.2008.299.","journal-title":"Leukemia"},{"key":"7813_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081793","volume":"13","author":"S Ito","year":"2021","unstructured":"Ito S, Sato T, Maeta T. Role and therapeutic targeting of SDF-1\u03b1\/CXCR4 axis in multiple myeloma. Cancers (Basel). 2021;13:1793. https:\/\/doi.org\/10.3390\/cancers13081793.","journal-title":"Cancers (Basel)"},{"key":"7813_CR30","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.3390\/cells11111775","volume":"11","author":"KE Luker","year":"2022","unstructured":"Luker KE, Luker GD. The CXCL12\/CXCR4\/ACKR3 signaling axis regulates PKM2 and glycolysis. Cells. 2022;11:1775. https:\/\/doi.org\/10.3390\/cells11111775.","journal-title":"Cells"},{"key":"7813_CR31","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s12149-025-02036-5","volume":"39","author":"DK Gauthaman","year":"2025","unstructured":"Gauthaman DK, Muthukrishnan I, Acharya KA, Simon S. Ga-68 pentixafor PET\/CT in multiple myeloma and its correlation with clinical parameters: institutional pilot study. Ann Nucl Med. 2025;39:588\u201399. https:\/\/doi.org\/10.1007\/s12149-025-02036-5.","journal-title":"Ann Nucl Med"},{"key":"7813_CR32","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1097\/RLU.0000000000005731","volume":"50","author":"H Kaur","year":"2025","unstructured":"Kaur H, Kumar S, Watts A, Singh C, Sachdeva MUS, Sreedharanunni S, et al. 68Ga-pentixafor PET\/CT-based response evaluation and its prognostic value in multiple myeloma: comparison with IMWG and 18F-FDG-based response. Clin Nucl Med. 2025;50:e331\u20139. https:\/\/doi.org\/10.1097\/RLU.0000000000005731.","journal-title":"Clin Nucl Med"},{"key":"7813_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00679-5","volume":"12","author":"P Hagen","year":"2022","unstructured":"Hagen P, Zhang J, Barton K. High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer J. 2022;12:83. https:\/\/doi.org\/10.1038\/s41408-022-00679-5.","journal-title":"Blood Cancer J"},{"key":"7813_CR34","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s43018-024-00784-3","volume":"5","author":"E Ramberger","year":"2024","unstructured":"Ramberger E, Sapozhnikova V, Ng YLD, Dolnik A, Ziehm M, Popp O, et al. The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities. Nat Cancer. 2024;5:1267\u201384. https:\/\/doi.org\/10.1038\/s43018-024-00784-3.","journal-title":"Nat Cancer"},{"key":"7813_CR35","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1200\/JCO.2016.68.6113","volume":"34","author":"A Larocca","year":"2016","unstructured":"Larocca A, Palumbo A. Optimizing treatment for elderly patients with newly diagnosed multiple myeloma: a personalized approach. J Clin Oncol. 2016;34:3600\u20134. https:\/\/doi.org\/10.1200\/JCO.2016.68.6113.","journal-title":"J Clin Oncol"},{"key":"7813_CR36","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1002\/ajh.70070","volume":"100","author":"SL Lim","year":"2025","unstructured":"Lim SL, Engelhardt M, Terpos E, Gay F, Van de Donk N, Einsele H, et al. European myeloma network consensus statement on functional high-risk multiple myeloma. Am J Hematol. 2025;100:2320\u201332. https:\/\/doi.org\/10.1002\/ajh.70070.","journal-title":"Am J Hematol"},{"key":"7813_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.61","volume":"8","author":"G Mellgard","year":"2024","unstructured":"Mellgard G, Gilligan M, Cliff ERS, Bhutani D, Mohyuddin GR, Eisenberger A, et al. Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. Hemasphere. 2024;8:e61. https:\/\/doi.org\/10.1002\/hem3.61.","journal-title":"Hemasphere"},{"key":"7813_CR38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/RLU.0000000000005813","volume":"50","author":"N Dreher","year":"2025","unstructured":"Dreher N, D\u00f6rrler AL, Kraus S, Rasche L, Higuchi T, Samnick S, et al. Myeloablative radioligand therapy targeting C-X-C motif chemokine receptor 4 in advanced multiple myeloma. Clin Nucl Med. 2025;50:495\u2013500. https:\/\/doi.org\/10.1097\/RLU.0000000000005813.","journal-title":"Clin Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07813-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07813-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07813-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:08:25Z","timestamp":1779422905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07813-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7813"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07813-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"23 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Medical Ethics Committee of Zhongnan Hospital of Wuhan University (approval no. #2022021), and this prospective clinical study had been registered at ClinicalTrials.gov (NCT05255926).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}